XOMA ROYALTY CORPORATION (XOMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$40.170.00%
Close 2026-07-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put XOMA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 13% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 56% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 42% in its worst 12-month stretch.
View RiskXOMA's growth depends on maintaining strong financial performance in a supportive healthcare sector. Recent financial performance is strong, with the company holding in the top half of its industry. It trades at a premium compared to peers, which suggests expectations are high. If XOMA reverses and cuts guidance after recently raising it, that could harm credibility. Peer multiples imply a price about 12% below where it trades. Our read is provisional.
Trailing returns as of 2026-07-14. XOMA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering XOMA (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare XOMA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| XOMA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put XOMA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Acquisition impacts revenue guidance and overall valuation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.